IRCT20200607047682N1 IRCT 2020-07-27 Shahid Beheshti University of Medical Sciences Clinical trial of Annual SZ drug in Covid-19 Clinical trial of the use of Annual SZ drug in the treatment of patients with Covid-19 disease in Emam Hosein hospital in Tehran. 2020-06-09 anticipated 60 Complete https://irct.ir/trial/48727 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly assigned to the case and control groups based on the admission codes, so that the even admission code is in the case group and the odd admission code is in the control group. 2-3 COVID-19. Intervention 1: Intervention group: The group treated with Anval SZ + azithromycin Anval S is a herbal product derived from the herb. The active ingredient is artemisinin, which is used in the treatment of malaria. The dose of TDS is 1-1.5 mg / kg. The time of use is 14 days for definite recovery, this medicine is in the form of oral syrup and is produced by the knowledge-based university of the Health of Living Life, observing all health principles. Intervention 2: The group that receives treatment according to the national routine protocol + azithromycin. The drugs in this group are hydroxychloroquine and keltra. Chloroquine is an anti-malarial drug and the dose is different depending on the phase of the disease and according to the national protocol. Hydroxychloroquine 200 mg daily for 8 days is administered as two stats together and then one every 12 hours for 5 days. About.Cltra tablets (lupinavir / ritonavir): 2 tablets of 50/200 every 12 hours for at least 5 days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is no info